Summary
Verity Leeson oversees the management of a portfolio of clinical trials in mental health, the majority of which involve the assessment of investigative medicinal products. This entails supervising a small team of trial coordinators, monitors and administrative staff to ensure the safe conduct of the trials with adherence to necessary pharmacovigilance. Day-to-day responsibilities include protocol and other document writing, preparation of ethical and regulatory submissions, proactive risk identification and supporting issue resolution, managing the budget and contractual arrangements, and collaboration on the development of new projects including funding applications.
Selected Publications
Journal Articles
Crawford MJ, Sanatinia R, Barrett B, et al., 2018, The clinical effectiveness and cost effectiveness of lamotrigine for people with borderline personality disorder: a randomized, placebo-controlled trial, American Journal of Psychiatry, Vol:175, ISSN:0002-953X, Pages:756-764
Barnes TRE, Leeson V, Paton C, et al., 2018, Amisulpride augmentation of clozapine for treatment-refractory schizophrenia: a double-blind, placebo-controlled trial, Therapeutic Advances in Psychopharmacology, Vol:8, ISSN:2045-1253, Pages:185-197
Barnes TRE, Leeson VC, Paton C, et al., 2017, Amisulpride augmentation in clozapine-unresponsive schizophrenia (AMICUS): a double-blind, placebo-controlled, randomised trial of clinical effectiveness and cost-effectiveness, Health Technology Assessment, Vol:21, ISSN:1366-5278, Pages:1-+
Barnes TR, Leeson VC, Paton C, et al., 2016, Antidepressant Controlled Trial For Negative Symptoms In Schizophrenia (ACTIONS): a double-blind, placebo-controlled, randomised clinical trial, Health Technology Assessment, Vol:20, ISSN:1366-5278
Leeson VC, Tyrer P, 2013, The advance of research governance in psychiatry: one step forward, two steps back, Epidemiology and Psychiatric Sciences, Vol:22, ISSN:2045-7960, Pages:313-320
Galve LBG, Wheeler-Kingshott CAM, Altmann DR, et al., 2012, CORTICAL THINNING OVER TWO YEARS FOLLOWING THE FIRST EPISODE OF PSYCHOSIS: RELATIONSHIP TO TREATMENT DURATION AND COGNITIVE IMPAIRMENT, Schizophrenia Research, Vol:136, ISSN:0920-9964, Pages:S205-S205
Leeson VC, Sharma P, Harrison M, et al., 2011, IQ Trajectory, Cognitive Reserve, and Clinical Outcome Following a First Episode of Psychosis: A 3-Year Longitudinal Study, Schizophrenia Bulletin, Vol:37, ISSN:0586-7614, Pages:768-777
Leeson VC, Harrison I, Ron MA, et al., 2011, The Effect of Cannabis Use and Cognitive Reserve on Age at Onset and Psychosis Outcomes in First-Episode Schizophrenia, Schizophrenia Bulletin
Barnett JH, Robbins TW, Leeson VC, et al., 2010, Assessing cognitive function in clinical trials of schizophrenia, Neuroscience and Biobehavioral Reviews, Vol:34, ISSN:0149-7634, Pages:1161-1177
Leeson VC, Robbins TW, Franklin C, et al., 2009, Dissociation of long-term verbal memory and fronto-executive impairment in first-episode psychosis, Psychological Medicine, Vol:39, ISSN:0033-2917, Pages:1799-1808
Leeson VC, Robbins TW, Matheson E, et al., 2009, Discrimination Learning, Reversal, and Set-Shifting in First-Episode Schizophrenia: Stability Over Six Years and Specific Associations with Medication Type and Disorganization Syndrome, Biological Psychiatry, Vol:66, ISSN:0006-3223, Pages:586-593